GENinCode

About:

GENinCode is a genetic testing business specializing in the risk assessment and prediction of cardiovascular disease.

Website: https://www.genincode.com

Twitter/X: GenIncode

Top Investors: Maven Capital Partners

Description:

GEN inCode specializes in cardiovascular disease risk. Cardiovascular disease is the leading cause of death and disability worldwide. GEN inCode products combine genetic and clinical data to risk assess patients and provide healthcare practitioners with advanced clinical information to evaluate and predict the onset of cardiovascular disease. Our products help inform patients of their health risk enabling them to make behavioral or ‘lifestyle’ changes whilst providing doctors with greater genetic insight and clinical information to determine the most effective treatment pathway (precision medicine). GEN inCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. Our polygenic tests combine clinical-genetic algorithms with AI to provide an advanced patient risk assessment to predict disease onset.

Total Funding Amount:

7.9M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Oxford, Oxfordshire, United Kingdom

Founded Date:

2018-01-01

Contact Email:

info(AT)genincode.com

Founders:

Jordi Puig, Matthew Walls

Number of Employees:

11-50

Last Funding Date:

2023-12-21

IPO Status:

Public

Industries:

© 2025 bioDAO.ai